Impax: generic launch was too risky

At opening arguments in the Federal Trade Commission’s tribunal, counsel to the drugmaker Impax argued that the company was not paid to delay generic competition and launching a generic form of Opana ER was too risky when it entered into a 2010 settlement with Opana’s patent-holder.

Unlock unlimited access to all Global Competition Review content